← All Mutual Funds

abrdn Life Sciences Investors

CIK: 0000884121 HQL Equity
Report date: 2026-02-27
AUM $555M
Expense Ratio
Category Equity
State MA
Fiscal Year End
Inception Date
Manager
Latest Filing 2026-02-27

About this Fund

abrdn Life Sciences Investors is a leading mutual fund company specializing in the art of asset management, providing a diverse range of investment solutions to cater to the unique needs of its discerning clientele. By leveraging its expertise in wealth management, the company offers a portfolio of meticulously crafted mutual funds that span across various asset classes, including equity, debt, and hybrid funds, thereby enabling investors to navigate the complexities of the financial landscape with confidence. The company's investment approach is centered around a deep understanding of the life sciences sector, with a focus on identifying high-growth opportunities that can potentially yield substantial returns over the long term. abrdn Life Sciences Investors' equity funds, for instance, are designed to capitalize on the growth potential of companies operating in the biotechnology, pharmaceutical, and medical devices industries, while its debt funds provide a stable source of income with relatively lower risk. The company also offers hybrid funds that combine the benefits of equity and debt investments, providing a balanced portfolio that can help mitigate risk while generating returns. For investors seeking a disciplined and systematic approach to investing, abrdn Life Sciences Investors offers a systematic investment plan, or SIP, which allows them to invest a fixed amount of money at regular intervals, thereby reducing the impact of market volatility. The company's investor-centric approach, coupled with its commitment to transparency and accountability, has earned it the trust of its clients, who value its ability to deliver tailored investment solutions that meet their unique financial objectives. With a strong focus on research and analysis, abrdn Life Sciences Investors' team of experienced investment professionals works tirelessly to identify emerging trends and opportunities in the life sciences sector, enabling the company to stay ahead of the curve and make informed investment decisions. By combining its expertise in asset management with a deep understanding of the life sciences industry, abrdn Life Sciences Investors has established itself as a trusted partner for investors seeking to navigate the complexities of the financial markets and achieve their long-term wealth management goals. The company's commitment to excellence, integrity, and client satisfaction has fostered a culture of trust and loyalty among its clients, who appreciate its dedication to delivering exceptional investment results and unparalleled customer service. As a result, abrdn Life Sciences Investors has become the go-to destination for investors seeking a reliable and experienced mutual fund company that can help them achieve their financial aspirations.

Holdings

From latest SEC N-PORT filing · US-listed stocks only

67 positions
# Security Name CUSIP Asset Type Weight % Value ($M) Quantity
1 ABEO Abeona Therapeutics Inc Since 2026-05-10 00289Y206 Equity (Common)
0.58%
$3.25 616,413
2 JBIO Jade Biosciences Inc Since 2026-05-10 008064206 Equity (Common)
0.77%
$4.28 277,555
3 ALLO Allogene Therapeutics Inc Since 2026-05-10 019770106 Equity (Common)
0.51%
$2.86 2,086,332
4 ALNY Alnylam Pharmaceuticals Inc Since 2026-05-10 02043Q107 Equity (Common)
2.06%
$11.42 28,726
5 AMGN Amgen Inc Since 2026-05-10 031162100 Equity (Common)
3.99%
$22.15 67,677
6 APGE Apogee Therapeutics Inc Since 2026-05-10 03770N101 Equity (Common)
0.49%
$2.73 36,103
7 AQST Aquestive Therapeutics Inc Since 2026-05-10 03843E104 Equity (Common)
0.30%
$1.65 255,905
8 ACLX Arcellx Inc Since 2026-05-10 03940C100 Equity (Common)
0.23%
$1.27 19,562
9 RCUS Arcus Biosciences Inc Since 2026-05-10 03969F109 Equity (Common)
0.26%
$1.44 60,608
10 ARQT Arcutis Biotherapeutics Inc Since 2026-05-10 03969K108 Equity (Common)
0.75%
$4.19 144,311
11 ARWR Arrowhead Pharmaceuticals Inc Since 2026-05-10 04280A100 Equity (Common)
1.44%
$7.99 120,388
12 AVTX Avalo Therapeutics Inc Since 2026-05-10 05338F306 Equity (Common)
0.31%
$1.73 95,426
13 AXSM Axsome Therapeutics Inc Since 2026-05-10 05464T104 Equity (Common)
1.30%
$7.23 39,565
14 BCRX BioCryst Pharmaceuticals Inc Since 2026-05-10 09058V103 Equity (Common)
0.26%
$1.47 187,803
15 CRBU Caribou Biosciences Inc Since 2026-05-10 142038108 Equity (Common)
0.40%
$2.21 1,388,905
16 CDXS Codexis Inc Since 2026-05-10 192005106 Equity (Common)
0.80%
$4.46 2,734,032
17 CRBP Corbus Pharmaceuticals Holdings Inc Since 2026-05-10 21833P301 Equity (Common)
0.80%
$4.43 543,719
18 CRNX Crinetics Pharmaceuticals Inc Since 2026-05-10 22663K107 Equity (Common)
2.22%
$12.34 265,141
19 DNLI Denali Therapeutics Inc Since 2026-05-10 24823R105 Equity (Common)
2.15%
$11.92 721,733
20 IRON Disc Medicine Inc Since 2026-05-10 254604101 Equity (Common)
0.88%
$4.86 61,234
21 DYN Dyne Therapeutics Inc Since 2026-05-10 26818M108 Equity (Common)
2.32%
$12.90 659,460
22 EWTX Edgewise Therapeutics Inc Since 2026-05-10 28036F105 Equity (Common)
1.58%
$8.75 352,615
23 EQ Equillium Inc Since 2026-05-10 29446K106 Equity (Common)
0.66%
$3.67 2,366,688
24 EVMN Evommune Inc Since 2026-05-10 30054Y107 Equity (Common)
0.54%
$2.99 174,581
25 EYPT EyePoint Inc Since 2026-05-10 30233G209 Equity (Common)
1.77%
$9.82 537,447
26 FULC Fulcrum Therapeutics Inc Since 2026-05-10 359616109 Equity (Common)
2.55%
$14.18 1,254,027
27 GILD Gilead Sciences Inc Since 2026-05-10 375558103 Equity (Common)
0.47%
$2.62 21,337
28 GRAL GRAIL Inc Since 2026-05-10 384747101 Equity (Common)
0.64%
$3.56 41,603
29 GH Guardant Health Inc Since 2026-05-10 40131M109 Equity (Common)
0.65%
$3.60 35,219
30 IDYA Ideaya Biosciences Inc Since 2026-05-10 45166A102 Equity (Common)
1.34%
$7.44 215,279
31 IMVT Immunovant Inc Since 2026-05-10 45258J102 Equity (Common)
2.02%
$11.22 441,498
32 IMUX Immunic Inc Since 2026-05-10 4525EP101 Equity (Common)
0.29%
$1.62 3,028,916
33 IONS Ionis Pharmaceuticals Inc Since 2026-05-10 462222100 Equity (Common)
0.41%
$2.29 28,926
34 IOVA Iovance Biotherapeutics Inc Since 2026-05-10 462260100 Equity (Common)
0.37%
$2.07 759,522
35 KRYS Krystal Biotech Inc Since 2026-05-10 501147102 Equity (Common)
0.63%
$3.48 14,121
36 LENZ LENZ Therapeutics Inc Since 2026-05-10 52635N103 Equity (Common)
0.45%
$2.49 155,610
37 NBIX Neurocrine Biosciences Inc Since 2026-05-10 64125C109 Equity (Common)
0.51%
$2.85 20,093
38 NUVL Nuvalent Inc Since 2026-05-10 670703107 Equity (Common)
1.26%
$6.97 69,310
39 ORKA Oruka Therapeutics Inc Since 2026-05-10 687604108 Equity (Common)
0.41%
$2.29 75,680
40 PSNL Personalis Inc Since 2026-05-10 71535D106 Equity (Common)
1.94%
$10.78 1,354,053
41 PRAX Praxis Precision Medicines Inc Since 2026-05-10 74006W207 Equity (Common)
0.95%
$5.25 17,814
42 DTIL Precision BioSciences Inc Since 2026-05-10 74019P207 Equity (Common)
0.78%
$4.34 1,043,752
43 REGN Regeneron Pharmaceuticals Inc Since 2026-05-10 75886F107 Equity (Common)
3.80%
$21.09 27,329
44 RVMD Revolution Medicines Inc Since 2026-05-10 76155X100 Equity (Common)
0.53%
$2.92 36,678
45 SRPT Sarepta Therapeutics Inc Since 2026-05-10 803607100 Equity (Common)
1.61%
$8.96 416,313
46 STTK Shattuck Labs Inc Since 2026-05-10 82024L103 Equity (Common)
0.35%
$1.94 531,177
47 SPRY ARS Pharmaceuticals Inc Since 2026-05-10 82835W108 Equity (Common)
1.22%
$6.77 581,057
48 SION Sionna Therapeutics Inc Since 2026-05-10 829401108 Equity (Common)
1.88%
$10.47 254,414
49 SLNO Soleno Therapeutics Inc Since 2026-05-10 834203309 Equity (Common)
0.81%
$4.51 97,455
50 SMMT Summit Therapeutics Inc Since 2026-05-10 86627T108 Equity (Common)
1.02%
$5.68 324,733
51 SNDX Syndax Pharmaceuticals Inc Since 2026-05-10 87164F105 Equity (Common)
1.41%
$7.83 372,792
52 TSHA Taysha Gene Therapies Inc Since 2026-05-10 877619106 Equity (Common)
1.01%
$5.62 1,021,063
53 TECX Tectonic Therapeutic Inc Since 2026-05-10 878972108 Equity (Common)
1.39%
$7.74 370,884
54 TEM Tempus AI Inc Since 2026-05-10 88023B103 Equity (Common)
1.00%
$5.58 94,511
55 TVTX Travere Therapeutics Inc Since 2026-05-10 89422G107 Equity (Common)
1.42%
$7.87 205,865
56 TCRX TScan Therapeutics Inc Since 2026-05-10 89854M101 Equity (Common)
0.17%
$0.94 941,693
57 RARE Ultragenyx Pharmaceutical Inc Since 2026-05-10 90400D108 Equity (Common)
2.06%
$11.43 497,078
58 PCVX Vaxcyte Inc Since 2026-05-10 92243G108 Equity (Common)
2.62%
$14.54 315,222
59 VIR Vir Biotechnology Inc Since 2026-05-10 92764N102 Equity (Common)
0.56%
$3.08 511,363
60 IMUX IMMUNIC INC. Since 2026-05-10 Derivative 2,311,826
61 IMUX IMMUNIC INC. Since 2026-05-10 Derivative
0.22%
$1.23 2,311,826
62 IMUX IMMUNIC INC. Since 2026-05-10 Derivative
0.08%
$0.46 2,311,826
63 XENE Xenon Pharmaceuticals Inc Since 2026-05-10 98420N105 Equity (Common)
2.15%
$11.92 266,030
64 DTIL PRECISION BIOSCIENCES Since 2026-05-10 Derivative
0.14%
$0.78 336,267
65 BHVN Biohaven Ltd Since 2026-05-10 Equity (Common)
1.41%
$7.83 693,452
66 JAZZ Jazz Pharmaceuticals PLC Since 2026-05-10 Equity (Common)
0.39%
$2.18 12,845
67 OCS Oculis Holding AG Since 2026-05-10 Equity (Common)
0.91%
$5.07 253,740
Frequently Asked Questions — abrdn Life Sciences Investors
What type of mutual fund is abrdn Life Sciences Investors?
abrdn Life Sciences Investors is a SEC-registered Equity fund, with $555M in assets under management. Equity funds invest primarily in a diversified portfolio of stocks and equities, aiming for long-term capital appreciation. They carry higher market risk than bond or money market funds but historically offer stronger long-term returns. Equity mutual funds can be further classified as large-cap, mid-cap, small-cap, growth, value, or sector-specific depending on their investment mandate. As of its latest SEC N-PORT filing, abrdn Life Sciences Investors holds 67 portfolio positions, all detailed in the holdings table on this page.
What are abrdn Life Sciences Investors's assets under management (AUM)?
abrdn Life Sciences Investors has $555M in assets under management (AUM) according to its most recent SEC N-PORT filing on StockSifting. AUM represents the total market value of all securities and other assets held by the fund as of the report date. A larger AUM generally signals a more established fund with greater institutional adoption, more trading liquidity, and potentially lower per-unit operational costs due to economies of scale. AUM changes daily as market prices fluctuate and as investors purchase or redeem fund shares — the figure shown here reflects the most recently available N-PORT disclosure, not the current real-time value. For the live figure, consult the fund's official website or its latest SEC EDGAR filing.
What are abrdn Life Sciences Investors's top holdings?
According to abrdn Life Sciences Investors's most recent SEC N-PORT filing, the fund's largest holdings by portfolio weight include Abeona Therapeutics Inc, Jade Biosciences Inc, Allogene Therapeutics Inc , among others. The complete list of all 67 holdings — including CUSIP, asset type, portfolio weight percentage, dollar value, and share quantity — is available in the holdings table above. Holdings data is sourced directly from SEC EDGAR N-PORT filings and reflects the fund's positions as of the report date shown at the top of this page. Due to the 60-day SEC disclosure lag, these positions may differ from the fund's current portfolio. For the latest holdings before public release, refer to SEC EDGAR directly.
What is abrdn Life Sciences Investors's expense ratio?
Expense ratio data for abrdn Life Sciences Investors is not currently available in StockSifting's database. The expense ratio is the annual fee charged by a mutual fund as a percentage of your investment, covering management fees and operational costs. It is one of the most important factors affecting net long-term returns — lower expense ratios allow more of a fund's gross performance to flow through to investors. For the most accurate and current expense ratio, refer to the fund's official prospectus or its SEC EDGAR filings. You can also contact us if you believe this data should be present.
Where can I find abrdn Life Sciences Investors's SEC filings?
abrdn Life Sciences Investors is required to file monthly portfolio reports (Form N-PORT) with the U.S. Securities and Exchange Commission (SEC). Its SEC Central Index Key (CIK) is 0000884121. You can access all of abrdn Life Sciences Investors's SEC filings — including N-PORT holdings disclosures, annual reports (Form N-CEN), and registration statements — directly on SEC EDGAR (CIK: 0000884121). N-PORT filings disclose the fund's complete portfolio holdings, fair value measurements, and certain risk metrics as of each filing period end date. StockSifting automatically parses these filings to populate the holdings table, AUM figures, and expense ratio displayed on this page, making the raw EDGAR data accessible without needing to download and parse XML files manually.
How current is abrdn Life Sciences Investors's holdings data on StockSifting?
Holdings data for abrdn Life Sciences Investors on StockSifting is sourced from its most recent SEC EDGAR N-PORT filing. Under SEC rules, registered investment companies must file N-PORT reports monthly, but these are made publicly available approximately 60 days after the reporting period end date. This means the holdings shown on this page reflect the fund's portfolio from roughly two months prior — not today's exact positions. The Report date displayed at the top of this page indicates exactly when the underlying data was current. If the fund has made significant portfolio changes since that date — responding to market events, earnings releases, or macro shifts — those changes will not be reflected here until the next N-PORT filing is released. For the most up-to-date holdings before the public disclosure window, refer to the fund's official website or SEC EDGAR directly. StockSifting is best used for fundamental research and historical portfolio analysis, not real-time trading decisions.